Medical Genetics

The Science of HT1: Genes, Enzymes, and Toxins

At a Glance

Tyrosinemia Type 1 (HT1) is a genetic disorder caused by FAH gene mutations that stop the body from breaking down the amino acid tyrosine. This leads to a buildup of a harmful toxin called succinylacetone, which can damage the liver, kidneys, and nerves. It is typically detected through newborn screening and confirmed via genetic testing.

To understand Tyrosinemia Type 1 (HT1), it helps to think of the body as a complex assembly line. When one part of the machine breaks down, the “raw materials” start to pile up, eventually turning into something harmful. In HT1, the assembly line is the process your body uses to break down tyrosine, an amino acid found in most protein-containing foods ^[1].

The Role of the FAH Gene

Every person has two copies of the FAH gene (one from each parent). This gene provides the instructions for making an enzyme called fumarylacetoacetate hydrolase (FAH) ^[2]^[3].

Think of the FAH enzyme as the final worker on the tyrosine assembly line. In children with HT1, both copies of the FAH gene have a mutation (a change in the genetic code), which means the FAH enzyme is either missing entirely or doesn’t work correctly ^[4]^[5]. Without this “worker” to finish the job, the process stops before it’s complete.

Why Succinylacetone is Dangerous

When the tyrosine assembly line stalls at the very end, the unfinished materials don’t just sit there—they transform into a toxic byproduct called succinylacetone (SA) ^[6].

Succinylacetone is the “smoking gun” of HT1. It is a highly specific marker, meaning if it is found in the blood or urine, it almost always points to HT1 ^[6]. SA causes damage in several ways:

Liver Damage: SA acts as a toxin to liver cells. If left unchecked, it can lead to scarring (cirrhosis) and can trigger the development of liver cancer (hepatocellular carcinoma) over time ^[7]^[8].
Kidney Dysfunction: The accumulation of SA can interfere with how the kidneys filter blood, potentially leading to Fanconi syndrome, where the kidneys leak important minerals and nutrients into the urine ^[9].
Nerve Crises: High levels of SA can cause episodes of intense pain, high blood pressure, or even temporary paralysis because the toxin interferes with how nerves function ^[10]^[11].

How Diagnosis Happens

Most children today are diagnosed through Newborn Screening (NBS). This is a simple heel-prick test performed shortly after birth.

Tandem Mass Spectrometry (MS/MS)

Lab technicians use a highly sensitive technology called tandem mass spectrometry to analyze the dried blood spot ^[1]. This machine can detect even tiny amounts of succinylacetone ^[6].

The Cut-off: Screening programs look for succinylacetone levels above their established normal baseline to flag a potential case ^[12].
Why not just test for Tyrosine?: While tyrosine levels are often high in HT1, they can also be high in newborns who don’t have the disease (a temporary condition called “transient tyrosinemia”). Testing specifically for succinylacetone is much more accurate ^[6]^[13].

Genetic Testing: The Final Confirmation

While the presence of succinylacetone is a strong indicator, doctors use genetic testing as the “gold standard” to confirm the diagnosis ^[14]^[15]. This involves sequencing the FAH gene to identify the specific mutations your child inherited ^[2]^[16].

Knowing the exact mutation is helpful for:

Family Planning: It allows parents to know their risk for future pregnancies and enables testing for siblings ^[16]^[17].
Certainty: It provides a definitive answer, moving from a biochemical suspicion to a genetic fact ^[14].

Currently, the specific type of mutation does not tell doctors exactly how severe the disease will be; that depends more on how quickly treatment is started and how well the medication and diet are followed ^[4]^[18].

Common questions in this guide

What causes Tyrosinemia Type 1 (HT1)?

HT1 is caused by a mutation in both copies of the FAH gene. This mutation prevents the body from making a working FAH enzyme, which is essential for properly breaking down the amino acid tyrosine from protein in the diet.

Why is succinylacetone dangerous?

When tyrosine isn't broken down completely, it turns into a toxic byproduct called succinylacetone. This toxin builds up in the body and can cause severe, progressive damage to the liver, kidneys, and nervous system if left untreated.

How is Tyrosinemia Type 1 diagnosed in newborns?

HT1 is typically detected through newborn screening using a heel-prick blood test. Laboratories use tandem mass spectrometry to look for elevated levels of succinylacetone, which is a highly specific and accurate marker for the disease.

Why do doctors perform genetic testing for HT1?

While newborn screening blood tests strongly indicate the presence of HT1, genetic testing is the gold standard used to confirm the diagnosis. It identifies the exact FAH gene mutations a child inherited, which provides diagnostic certainty and is highly valuable for family planning.

Curated prompts to bring to your next appointment.

1.What was the level of succinylacetone found in my child's newborn screening?
2.Can you explain the specific FAH gene mutations my child has and what they mean for our family?
3.Are there any other biochemical markers, like alpha-fetoprotein (AFP), that we are tracking alongside succinylacetone?
4.Does the presence of succinylacetone mean there is already damage to the liver or kidneys, or did we catch it early enough to prevent it?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (18)

1
Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update.
Giguère Y, Berthier MT
Advances in experimental medicine and biology 2017; (959()):139-146 doi:10.1007/978-3-319-55780-9_13.
PMID: 28755192
2
Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G, Tanguay RM
Advances in experimental medicine and biology 2017; (959()):9-21 doi:10.1007/978-3-319-55780-9_2.
PMID: 28755181
3
Identification of the Mutations Spectrum in the Fumarylacetoacetate Hydrolase Gene in Tyrosinemia Type 1 Patients in Northeastern Iran.
Yazdani AH, Keyfi F, Nahid S, et al.
Biochemical genetics 2026; (64(2)):1572-1586 doi:10.1007/s10528-025-11102-6.
PMID: 40237876
4
Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
Morrow G, Angileri F, Tanguay RM
Advances in experimental medicine and biology 2017; (959()):25-48 doi:10.1007/978-3-319-55780-9_3.
PMID: 28755182
5
Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I.
Morrow G, Dreumont N, Bourrelle-Langlois M, et al.
Molecular genetics and metabolism 2019; (127(1)):58-63 doi:10.1016/j.ymgme.2019.01.019.
PMID: 30954369
6
Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.
Varughese B, Madrewar D, Polipalli SK, Kapoor S
Indian journal of clinical biochemistry : IJCB 2022; (37(1)):40-50 doi:10.1007/s12291-020-00944-z.
PMID: 35125692
7
Oncometabolite modification of Keap1 links GSTZ1 deficiency with cancer.
Guo W, Zhou BP
Genes & diseases 2019; (6(4)):333-334 doi:10.1016/j.gendis.2019.10.005.
PMID: 31832512
8
GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone.
Yang F, Li J, Deng H, et al.
The EMBO journal 2019; (38(15)):e101964 doi:10.15252/embj.2019101964.
PMID: 31267557
9
Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1.
Dweikat I, Qawasmi N, Najeeb A, Radwan M
Metabolism open 2021; (9()):100083 doi:10.1016/j.metop.2021.100083.
PMID: 33598652
10
Nitisinone treatment protect hereditary tyrosinemia type I patients against inflammation, DNA and protein oxidative damage by decreasing succinylacetone levels.
Mascarello RB, Faverzani JL, Lopes FF, et al.
Metabolic brain disease 2025; (40(7)):275 doi:10.1007/s11011-025-01719-2.
PMID: 41003839
11
Heme as an initial treatment for severe decompensation in tyrosinemia type 1.
Neeleman RA, Wilson JHP, Williams M, Langendonk JG
Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(2)):437-438 doi:10.1038/s41436-019-0658-z.
PMID: 31570800
12
Evaluation of Neonatal Screening Programs for Tyrosinemia Type 1 Worldwide.
Kuypers AM, Bouva MJ, Loeber JG, et al.
International journal of neonatal screening 2024; (10(4)) doi:10.3390/ijns10040082.
PMID: 39728402
13
Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
Stinton C, Geppert J, Freeman K, et al.
Orphanet journal of rare diseases 2017; (12(1)):48 doi:10.1186/s13023-017-0599-z.
PMID: 28274233
14
Diagnosis and the importance of early treatment of tyrosinemia type 1: A case report.
Škaričić A, Zekušić M, Fumić K, et al.
Clinical mass spectrometry (Del Mar, Calif.) 2019; (12()):1-6 doi:10.1016/j.clinms.2019.01.005.
PMID: 34841073
15
Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review.
Daou KN, Barhoumi A, Bassyouni A, Karam PE
Frontiers in pediatrics 2021; (9()):698577 doi:10.3389/fped.2021.698577.
PMID: 34422723
16
Identification and functional characterization of a novel homozygous intronic variant in the fumarylacetoacetate hydrolase gene in a Chinese patient with tyrosinemia type 1.
Chen J, Sun J, Li X, Du M
BMC medical genomics 2022; (15(1)):251 doi:10.1186/s12920-022-01406-6.
PMID: 36463171
17
The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1).
Chi H, Gan C, Jiang Y, et al.
Molecular genetics & genomic medicine 2023; (11(1)):e2090 doi:10.1002/mgg3.2090.
PMID: 36369907
18
Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant.
Ibarra-González I, Fernández-Lainez C, Alcántara-Ortigoza MA, et al.
Molecular genetics & genomic medicine 2019; (7(12)):e937 doi:10.1002/mgg3.937.
PMID: 31568711

This page provides educational information about the science and diagnosis of Tyrosinemia Type 1 (HT1). It is not a substitute for professional medical advice, diagnosis, or treatment from your pediatric metabolic specialist or genetic counselor.

Get notified when new evidence is published on Tyrosinemia type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents